of our next-generation IO therapy, IBI363 (PD-1/IL-2α-bias). If successful, this trial could bring a potentially transformative treatment to patients with squamous NSCLC worldwide, who currently have limited options after checkpoint inhibitor...
baseline to Week 8. "Completing enrollment in CYPRESS marks a major step toward bringing this potentially transformative therapy to patients with symptomatic nOH due to MSA – an underserved patient population in dire need for a new, effective and...
in the lung arteries. VTB-10 is a first-in-class drug candidate developed using VASTHERA’s proprietary Redoxizyme™ platform. VASTHERA identified a deficiency of the enzyme peroxiredoxin (PRX) in PAH lesions and developed VTB-10, a small molecule...
solution that enables soft tissue regeneration in the breast — positioning CollPlant to be first-to-market with a transformative solution. Strong Preclinical Progress: Successfully 3D bioprinted 200cc commercial-size implants with enhanced...
GoodRx the leading platform for medication savings in the U.S., announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for...
PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication...
WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets...
pediatrician and Genexa partner. “Genexa reflects what we as doctors want to see more of: clean, simple, and effective formulas for acute symptom relief.” The Brand at the Center of a Clean Medicine Movement: These findings reinforce broader market...
their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study. This was based on the healthy volunteer study using semaglutide...
the Board of Abcentra and Managing Partner of Glenbarr Partners. "We believe orticumab has the potential to become a transformative therapy in cardiovascular disease and are proud to support this innovative approach targeting coronary inflammation,...
for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to iron sucrose. WARNINGS AND PRECAUTIONS Hypersensitivity reactions: Serious...
clients fully integrated services—including GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation and aseptic fill/finish—within a single U.S.-based location. This streamlined approach simplifies coordination,...
Chief Scientific Officer, Chimerix, a Jazz Pharmaceuticals Company. "We're proud to deliver precisely the kind of transformative innovation we strive for, and we congratulate our combined Chimerix and Jazz team, and the community who worked...
Disease at Roche Diagnostics. "TAGS technology allows for the detection of more targets on a high-throughput platform, which supports diagnostic stewardship while reaching a broader patient population." This launch further expands Roche's...
AliveDx, the global in vitro diagnostics company that aims to transform patient care, announces that the MosaiQ AiPlex® Vasculitis (VAS) assay achieved IVDR-CE Mark. This means that the MosaiQ AiPlex VAS assay is now available for clinical use in...
visible signs of aging linked to collagen loss and glycation. It is engineered with double-patented technology and formulated with a potent 34.6% concentration of Flavo-Proxylane™, Rhamnose, and Gentiana Lutea Root Extract. This serum formula with...
on the success of the Company’s THC Inhaler introduced earlier this year. The new metered dose inhaler delivers a precise formulation of minor cannabinoid CBN and THC in a consistent, smoke-free format. Designed for nighttime use, the product...
primary IC-MPGN, and in C3G patients with post-transplant disease recurrence. “EMPAVELI has the potential to be truly transformational for patients with C3G and primary IC-MPGN, who until now have had very few treatment options. In the largest...
development is one of the biggest threats to progress in biotech," said Dave Johnson, co-founder and CEO of Dash Bio and former Chief Data & AI Officer at Moderna. "Our platform was designed the right way from day one: real automation, real...
more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii....
